Mismatch restore (MMR) germline alterations are enriched amongst sufferers with uveal melanoma (UM), in line with a research published on-line June 18 in JAMA Ophthalmology.
Anaïs Le Ven, from Inserm U1339 in Paris, and colleagues performed a potential cohort study involving 381 consecutive sufferers recognized with UM between July 2021 and February 2023 to establish new genetic alterations predisposing for UM. All individuals consented to prolonged genetic testing; a panel of 122 genes predisposing to cancer have been analyzed by focused sequencing on germline DNA.
The researchers recognized 79 pathogenic variants (PVs) in 70 individuals. Twenty-one of those have been present in clinically related genes, with an enrichment within the MMR genes concerned in Lynch syndrome, suggesting that MMR germline PVs might predispose to UM.
One tumor from a participant carrying an MLH1 germline PV exhibited a monosomy 3, with lack of the wild-type allele of MLH1, which is positioned on chromosome 3. Loss of MLH1 expression was seen by immunohistochemistry; whole-genome sequencing of this tumor recognized MMR variant signatures SBS6, ID1, and ID2.
“These findings counsel that MMR germline alterations might clarify not less than a portion of UM genetics, and that UM may very well be a part of the Lynch syndrome spectrum,” the authors write.
One creator disclosed ties to the pharmaceutical business; a second creator holds associated patents.
More data:
Anaïs Le Ven et al, Uveal Melanoma and the Lynch Syndrome Tumor Spectrum, JAMA Ophthalmology (2025). DOI: 10.1001/jamaophthalmol.2025.1779
Citation:
Mismatch restore germline pathogenic variants might predispose to uveal melanoma ( 21)
26
mismatch-germline-pathogenic-variants-predispose.html
.
. The content material is offered for data functions solely.